Evaluation of Glycemic Control and Predictors of Severe Illness and Death in Patients With Diabetes Hospitalized With COVID-19
Milosavljevic et al., Journal of Community Hospital Internal Medicine Perspectives, doi:10.55729/2000-9666.1127
Milosavljevic et al., Evaluation of Glycemic Control and Predictors of Severe Illness and Death in Patients With Diabetes.., Journal of Community Hospital Internal Medicine Perspectives, doi:10.55729/2000-9666.1127
Abstract: Journal of Community Hospital Internal Medicine Perspectives
Volume 12
Issue 6
Article 5
2022
Evaluation of Glycemic Control and Predictors of Severe Illness
and Death in Patients With Diabetes Hospitalized With COVID-19
Jovan Milosavljevic
Department of Medicine, Sinai Hospital of Baltimore, Baltimore, jovmilosa@gmail.com
Navya Reddy Perkit
Department of Medicine, Sinai Hospital of Baltimore, Baltimore
Sakshi Jhawar
Department of Medicine, Sinai Hospital of Baltimore, Baltimore
Melbin Thomas
Department of Medicine, Sinai Hospital of Baltimore, Baltimore
Justin Ling
Department of Medicine, Sinai Hospital of Baltimore, Baltimore
See next page for additional authors
Follow this and additional works at: https://scholarlycommons.gbmc.org/jchimp
Recommended Citation
Milosavljevic, Jovan; Perkit, Navya Reddy; Jhawar, Sakshi; Thomas, Melbin; Ling, Justin; Amankwah,
Samuel; and Thomas, Asha Mary (2022) "Evaluation of Glycemic Control and Predictors of Severe Illness
and Death in Patients With Diabetes Hospitalized With COVID-19," Journal of Community Hospital Internal
Medicine Perspectives: Vol. 12: Iss. 6, Article 5.
DOI: 10.55729/2000-9666.1127
Available at: https://scholarlycommons.gbmc.org/jchimp/vol12/iss6/5
This Research Article is brought to you for free and open access by the Journal at GBMC Healthcare Scholarly
Commons. It has been accepted for inclusion in Journal of Community Hospital Internal Medicine Perspectives by
an authorized editor of GBMC Healthcare Scholarly Commons. For more information, please contact
GBMCcommons@gbmc.org.
Evaluation of Glycemic Control and Predictors of Severe Illness and Death in
Patients With Diabetes Hospitalized With COVID-19
Authors
Jovan Milosavljevic, Navya Reddy Perkit, Sakshi Jhawar, Melbin Thomas, Justin Ling, Samuel Amankwah,
and Asha Mary Thomas
This research article is available in Journal of Community Hospital Internal Medicine Perspectives:
https://scholarlycommons.gbmc.org/jchimp/vol12/iss6/5
Jovan Milosavljevic a,*, Navya R. Perkit a, Sakshi Jhawar a, Melbin Thomas a, Justin Ling a,
Samuel Amankwah a, Asha M. Thomas b
a
b
Department of Medicine, Sinai Hospital of Baltimore, Baltimore, MD 21215, USA
Division of Endocrinology, Department of Medicine, Sinai Hospital of Baltimore, Baltimore, MD 21215, USA
Abstract
Objectives: To identify risk factors for severe disease and death among patients with diabetes and coronavirus disease
2019 (COVID-19) infection.
Methods: This retrospective cohort study conducted at three hospitals included 733 consecutive patients with DM
admitted with confirmed COVID-19 (March 1 - December 31, 2020). Multivariable logistic regression was performed to
identify predictors of severe disease and death.
Results: The mean age was 67.4 ± 14.3 years, 46.9% were males and 61.5% were African American. Among all patients,
116 (15.8%) died in the hospital. A total of 317 (43.2%) patients developed severe disease, 183 (25%) were admitted to an
ICU and 118 (16.1%) required invasive mechanical ventilation. Increasing BMI (OR, 1.13; 95% CI, 1.02e1.25), history of
chronic lung disease (OR, 1.49; 95% CI, 1.05e2.10) and increasing time since the last HbA1c test (OR, 1.25; 95% CI,
1.05e1.49) were the preadmission factors associated with increased odds of severe disease. Preadmission use of metformin (OR, 0.67; 95% CI, 0.47e0.95) or GLP-1 agonists (OR, 0.49; 95% CI, 0.27e0.87) was associated with decreased odds
of severe disease. Increasing age (OR, 1.21; 95% CI,..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.